- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03907774
MPN Podcast Pilot Study
A Feasibility Study of 12 Weeks of Smartphone-based Health Education Podcasts in Myeloproliferative Neoplasm Patients
Study Overview
Status
Conditions
Detailed Description
Interested patients will complete an eligibility screening using a REDCap link (see eligibility survey). The eligibility screening takes 5-10 minutes to complete.
If ineligible, the participant will be sent an email notification (see study protocol).
If eligible, the potential participant will be sent a link to a video containing a detailed overview of the informed consent as well as a link to sign the informed consent. There will be a place for the participant to type in their electronic signature, which will constitute their consent to participate in the study (see informed consent). After signing the informed consent, participants will be sent an additional email with their study start date, which will fall on the next Monday after signing the informed consent so that all participants begin participating on a Monday. On the day of their study start date, participants will be sent a welcome email as well as a link to complete the baseline self-report measure (listed below) via REDCap.
Within the welcome email, there will be step-by-step instructions for accessing the podcast intervention via a smartphone app. Participants will be asked to view 60 minutes per week of podcasts through a smartphone app. The podcast videos will contain general cancer-related health education material. A total of 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a weekly log (see weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
The investigators will use self-report questionnaires at baseline (week 0), mid-point (week 6), and post-intervention (week 12) administered via REDCap (see baseline, mid-point, and post-intervention surveys). Demographics data and MPN-related health information will be collected at baseline and satisfaction-related data will be collected within the post-intervention questionnaire. Feasibility measures will include acceptability, demand, and practicality.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Arizona State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have a diagnosis of essential thrombocythemia, polycythemia vera, or myelofibrosis identified by treating physician
- Have access to a smartphone on a regular basis
- Have access to reliable home internet
- Read and understand English
- 18 years or older
Exclusion Criteria:
- Any planned change in pharmacologic intervention (i.e., new drug, bone marrow transplant) during the study interval (i.e., 12 weeks)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of Podcast App: satisfaction survey
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Acceptability will be measured with a satisfaction survey.
Benchmarks for acceptability include greater than or equal to 70% response to the following questions in the survey: 1) satisfaction with the app's content, 2) intending to continue using the app, 3) enjoying using the apps, and 4) recommending it to other MPN patients.
The % of participants indicating responses to the four prior questions will be considered "acceptable" if all four questions are responded to with a greater than or equal to 70% response rate.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Demand of Podcast App
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Demand will be measured using adherence to the podcast prescription.
Podcast viewing will be tracked by the smartphone app developers and reported to the Principal Investigator.
Adherence benchmarks are defined as an average of greater than or equal to 49 minutes per week of podcast viewing across all participants (i.e., greater than or equal to 70% of prescribed podcasts).
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Practicality of Podcast App: participation rate
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Practicality will be measured through a participation rate greater than or equal to 70%, with completion being defined as completing all three self-report questionnaires.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MPN Total Symptom Burden (severity and symptomology)
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
A 10-item, validated form that calculates total symptom burden score through the MPN Symptom Assessment Form Total Symptom Score.
A higher score indicates a worse MPN-specific symptom burden; scores range from 0-100.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Fatigue
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
A single-item fatigue question taken from the MPN Symptom Assessment Form; scores can range from 0-10.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Anxiety
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH Promis) Anxiety Short Form; this scale consists of a series of questions that are tallied up into a sum score and converted to a standardized t-score.
A higher score represents a higher presence, not necessarily a better or worse score, of the item being measured; scores range from 36.3-82.7.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Depression
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH Promis) Depression Adult Short Form; this scale consists of a series of questions that are tallied up into a sum score and converted to a standardized t-score.
A higher score represents a higher presence, not necessarily a better or worse score, of the item being measured; scores range from 41.0-79.4.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Sleep Disturbance
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH Promis) Sleep Disturbance Adult Short Form; this scale consists of a series of questions that are tallied up into a sum score and converted to a standardized t-score.
A higher score represents a higher presence, not necessarily a better or worse score, of the item being measured; scores range from 32.0-73.3.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Sexual Function
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH Promis) Sexual Function consisting of five sub-scales; these scales consist of a series of questions that are tallied up into a sum score and converted to a standardized t-score.
A higher score represents a higher presence, not necessarily a better or worse score, of the item being measured; the five sub-scales include vaginal discomfort (score range of 33.2-77.08),
lubrication (score range of 30.99-69.26),
erectile dysfunction (score range of 30.72-68.47),
satisfaction with sex life (score range of 29.59-72.01),
and interest in sexual activity (score range of 32.02-76.17).
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Pain Intensity: NIH Promis Pain Intensity Adult Short Form
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH Promis) Pain Intensity Adult Short Form; this scale consists of a series of questions that are tallied up into a sum score and converted to a standardized t-score.
A higher score represents a higher presence, not necessarily a better or worse score, of the item being measured; scores range from 30.7-71.8.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Global Health
Time Frame: Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH Promis) Global Health consisting of Physical Health and Mental Health sub-scales; these scales consist of a series of questions that are tallied up into a sum score and converted to a standardized t-score.
A higher score represents a higher presence, not necessarily a better or worse score, of the item being measured; scores ranges for physical health are 16.2-67.7,
and score ranges for mental health are 21.1-67.6.
|
Change from baseline to mid-point (week 6) and post-intervention (week 12)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00008403
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloproliferative Neoplasm, Unclassifiable
-
Sociedad de Lucha Contra el Cáncer del EcuadorCompletedMyeloproliferative Disorders | Myeloproliferative Neoplasm | Myeloproliferative Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative Disease, Not ClassifiedEcuador
-
Inge Marie SvaneCompletedEssential Thrombocythemia | Myelofibrosis | Myeloproliferative Neoplasm, UnclassifiableDenmark
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Minimal Residual Disease | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Acute Myeloid Leukemia in RemissionUnited States
-
Jacqueline Garcia, MDNational Institutes of Health (NIH)RecruitingAcute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant | MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Neutrophilic Leukemia | Myeloid Neoplasm | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma | Myelodysplastic/Myeloproliferative Diseases | MDS | Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableUnited States
-
University of WashingtonRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, UnclassifiableUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | High-risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Secondary Myelofibrosis in Myeloproliferative Disease
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPrimary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Bellicum PharmaceuticalsWithdrawnRecurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditionsUnited States